Comparison of clinicopathological characteristics and survival outcomes between gallbladder mucinous adenocarcinoma and gallbladder adenocarcinoma: A propensity score-matched study

Table 2 Univariate and multivariate Cox analysis of overall survival and cancer-specific survival of gallbladder mucinous adenocarcinoma patients

Characteristic	Overall survival				Cancer-specific survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Age (yr)
< 60	Reference		Reference		Reference		Reference
≥ 60	1.4 (0.96-2.03)	0.08	NA	NA	1.46 (0.98-2.18)	0.063	NA	NA
Sex
Female	Reference		Reference		Reference		Reference
Male	0.92 (0.66-1.29)	0.632	NA	NA	1.01 (0.71-1.44)	0.943	NA	NA
Race
White	Reference		Reference		Reference		Reference
Black	1.18 (0.79-1.75)	0.423	NA	NA	1.23 (0.81-1.87)	0.322	NA	NA
Others	1.24 (0.74-2.07)	0.41	NA	NA	1.22 (0.71-2.11)	0.468	NA	NA
Marital status
Married	Reference		Reference		Reference		Reference
Unmarried	1.02 (0.74-1.4)	0.914	NA	NA	1 (0.71-1.4)	0.998	NA	NA
Unknown	1.16 (0.42-3.18)	0.78	NA	NA	1.25 (0.45-3.44)	0.671	NA	NA
Histological grade
Well differentiated	Reference		Reference		Reference		Reference
Moderately differentiated	1.51 (0.86-2.64)	0.152	1.27 (0.7-2.3)	0.4291	1.26 (0.71-2.23)	0.434	1.01 (0.56-1.84)	0.9612
Poorly differentiated	1.84 (1.03-3.27)	0.039	1.45 (0.78-2.68)	0.2354	1.64 (0.91-2.95)	0.097	1.18 (0.64-2.18)	0.5956
Unknown	2.14 (1.21-3.76)	0.008	1.09 (0.54-2.21)	0.8144	1.93 (1.09-3.41)	0.025	0.61 (0.3-1.22)	0.1601
Surgery
Yes	Reference		Reference		Reference		Reference
No	2.37 (1.7-3.32)	< 0.001	2.27 (1.31-3.96)	0.0037	2.43 (1.71-3.45)	< 0.001	2.05 (1.15-3.66)	0.0151
Chemotherapy
Yes	Reference		Reference		Reference		Reference
No/Unknown	1.94 (1.42-2.65)	< 0.001	6.41 (4.07-10.09)	< 0.001	1.84 (1.33-2.57)	< 0.001	5.24 (3.44-8)	< 0.001
Radiotherapy
Yes	Reference		Reference		Reference		Reference
No/Unknown	1.57 (1.04-2.38)	0.033	0.72 (0.42-1.22)	0.2204	1.35 (0.89-2.06)	0.162	NA	NA
AJCC
I	Reference		Reference		Reference		Reference
II	2.85 (0.38-21.47)	0.311	2.67 (0.27-26.23)	0.3996	1.91 (0.25-14.82)	0.535	2.73 (0.35-21.46)	0.3393
III	5.28 (0.73-38.24)	0.1	7.51 (0.84-66.94)	0.0707	4.61 (0.64-33.5)	0.131	12.31 (1.63-93.01)	0.015
IV	9.94 (1.38-71.58)	0.023	28.99 (2.83-297.29)	0.0046	8.8 (1.22-63.37)	0.031	32.69 (3.81-280.34)	0.0015
T stage
T1	Reference		Reference		Reference		Reference
T2	0.87 (0.38-1.95)	0.727	1.32 (0.47-3.72)	0.5965	0.65 (0.28-1.5)	0.315	NA	NA
T3	2.16 (0.99-4.69)	0.052	1.9 (0.76-4.75)	0.1676	1.88 (0.86-4.1)	0.112	NA	NA
T4	2.59 (1.08-6.23)	0.033	1.05 (0.37-2.95)	0.9314	2.34 (0.97-5.66)	0.06	NA	NA
Unknown	2.08 (0.87-4.96)	0.097	0.6 (0.22-1.65)	0.3196	2.05 (0.86-4.87)	0.106	NA	NA
N stage
N0	Reference		Reference		Reference		Reference
N1	1.08 (0.76-1.52)	0.679	1.1 (0.73-1.68)	0.6426	1.14 (0.79-1.64)	0.494	1.09 (0.72-1.64)	0.6778
N2	2.17 (1.14-4.12)	0.018	0.72 (0.34-1.51)	0.3848	2.19 (1.11-4.3)	0.023	0.82 (0.39-1.7)	0.5865
Unknown	1.79 (1.06-3.05)	0.031	1.43 (0.74-2.76)	0.2833	2.08 (1.21-3.56)	0.008	1.18 (0.63-2.19)	0.6084
M stage
M0	Reference		Reference		Reference		Reference
M1	2.17 (1.58-2.98)	< 0.001	0.85 (0.37-1.95)	0.705	2.25 (1.61-3.14)	< 0.001	0.94 (0.46-1.91)	0.8572

HR: Hazard ratio; NA: Not available; AJCC: American Joint Committee on Cancer.